Researchers have identified new biomarkers that may help predict response to checkpoint inhibitors, a type of immunotherapy. These biomarkers, which can be identified through various methods including liquid biopsy and artificial intelligence-based approaches, may be applicable to several types of cancer, including kidney, head and neck, lung, Merkel cell, and melanoma. The discovery of these biomarkers could potentially allow for earlier insight into treatment response and more personalized immunotherapy approaches.